#1 Clinical Trials Search in Europe

Lanifibranor

Lanifibranor is an innovative drug currently being studied in clinical trials for its potential to treat various metabolic disorders, including nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes. This article explores the ongoing research into Lanifibranor’s safety, efficacy, and pharmacokinetics across different patient populations and dosing regimens.

Table of Contents

What is Lanifibranor?

Lanifibranor, also known as IVA337, is a new drug being developed to treat various liver and metabolic disorders[1]. It is currently undergoing clinical trials to evaluate its effectiveness and safety in patients with specific conditions.

How Does Lanifibranor Work?

Lanifibranor is classified as a pan-peroxisome proliferator-activated receptor (PPAR) agonist[1]. This means it activates certain proteins in the body called PPARs, which play important roles in regulating metabolism, inflammation, and cell growth. By targeting these receptors, Lanifibranor aims to improve various aspects of liver and metabolic health.

What Conditions Does Lanifibranor Treat?

Based on the ongoing clinical trials, Lanifibranor is being studied for the treatment of the following conditions:

  • Nonalcoholic Fatty Liver Disease (NAFLD): A condition where excess fat accumulates in the liver of people who drink little or no alcohol[2].
  • Type 2 Diabetes (T2DM): A chronic condition that affects the way your body processes blood sugar (glucose)[2].

Researchers are particularly interested in how Lanifibranor might help patients who have both NAFLD and type 2 diabetes, as these conditions often occur together and can worsen each other.

Current Clinical Trials

Several clinical trials are currently underway to evaluate Lanifibranor:

  1. Pharmacokinetic Study in Chinese Subjects: This study aims to understand how Lanifibranor is processed in the bodies of healthy Chinese adults[1].
  2. Efficacy in Patients with Type 2 Diabetes and NAFLD: This trial is investigating how well Lanifibranor works in reducing liver fat and improving various metabolic parameters in patients with both conditions[2].
  3. Safety and Dosing Study: This study is evaluating the safety and appropriate dosing of Lanifibranor in healthy volunteers[3].

Dosage and Administration

The dosage of Lanifibranor is still being determined through clinical trials. Current studies are testing doses ranging from 800 mg to 1200 mg per day, taken orally[1][2]. It’s important to note that the optimal dose may vary depending on the condition being treated and individual patient factors.

Safety and Side Effects

As Lanifibranor is still in the clinical trial phase, its full safety profile is not yet established. Researchers are closely monitoring for any adverse events, which may include:

  • Changes in vital signs (blood pressure, pulse)
  • Abnormalities in clinical laboratory tests (blood and urine tests)
  • Changes in electrocardiogram (ECG) parameters (heart rhythm measurements)
  • Any other unexpected side effects[3]

It’s important to remember that Lanifibranor is not yet approved for general use, and its safety and effectiveness are still being evaluated. Patients interested in this treatment should discuss potential clinical trial participation with their healthcare providers.

Aspect Details
Drug Name Lanifibranor (also known as IVA337)
Drug Class Pan-peroxisome proliferator-activated receptor (PPAR) agonist
Conditions Studied Nonalcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes (T2DM)
Dosages 800 mg/day, 1200 mg/day (varies by study)
Study Designs Randomized, double-blind, placebo-controlled trials
Primary Outcomes Changes in intrahepatic triglycerides, pharmacokinetic parameters, safety assessments
Secondary Outcomes Liver fibrosis markers, insulin sensitivity, lipid profiles, glycemic control
Study Populations Healthy volunteers, patients with T2DM and NAFLD, Chinese subjects
Key Measurements MRI/MRS imaging, blood tests, euglycemic hyperinsulinemic clamp, liver stiffness assessments

FAQ

  • What is Lanifibranor? Lanifibranor is a pan-peroxisome proliferator-activated receptor (PPAR) agonist. It is being studied as a potential treatment for metabolic disorders such as nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes.
  • What are the main goals of the clinical trials involving Lanifibranor? The clinical trials aim to evaluate Lanifibranor's safety, efficacy, and pharmacokinetic profile in different populations. They also seek to understand its effects on liver fat content, insulin sensitivity, and other metabolic parameters.
  • What dosages of Lanifibranor are being studied? Various dosages are being studied, including 800 mg and 1200 mg daily doses. Some trials are exploring single doses, while others are investigating multiple doses over extended periods.
  • Who are the participants in these clinical trials? The trials involve different groups, including healthy adult Chinese subjects, patients with type 2 diabetes and NAFLD, and healthy volunteers for safety studies. Each trial has specific inclusion criteria based on its objectives.
  • What are some of the key outcomes being measured in these trials? Key outcomes include changes in intrahepatic triglycerides, liver stiffness, glycemic control, lipid profiles, and various pharmacokinetic parameters such as maximum plasma concentration and drug clearance. Safety assessments, including adverse events and changes in vital signs, are also crucial components of these studies.

Ongoing Clinical Trials on Lanifibranor

  • Study on the Effectiveness and Safety of Lanifibranor for Adults with Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis Stages F2/F3

    Not recruiting

    3 1
    Investigated drugs:
    Belgium Bulgaria Czechia France Germany Hungary +5

Glossary

  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Nonalcoholic Fatty Liver Disease (NAFLD): A condition where excess fat accumulates in the liver of people who drink little or no alcohol.
  • Type 2 Diabetes (T2DM): A chronic condition that affects the way your body metabolizes glucose (sugar), leading to high blood sugar levels.
  • Intrahepatic Triglycerides (IHTG): Fat stored within liver cells, often measured to assess the severity of fatty liver disease.
  • Euglycemic Hyperinsulinemic Clamp: A technique used to measure insulin sensitivity by maintaining a constant blood glucose level while infusing insulin.
  • De Novo Lipogenesis (DNL): The process by which the body produces new fat from excess carbohydrates.
  • HbA1c: A blood test that measures average blood sugar levels over the past 2-3 months.
  • Magnetic Resonance Elastography (MRE): An imaging technique used to measure the stiffness of soft tissues, particularly useful in assessing liver fibrosis.
  • Vibration Controlled Transient Elastography (VCTE): A non-invasive method to assess liver stiffness and fat content, often performed using a device called FibroScan.
  • Cytokeratin 18: A protein released during liver cell death, used as a biomarker for liver damage and fibrosis.

References

  1. https://clinicaltrials.gov/study/NCT06126562
  2. https://clinicaltrials.gov/study/NCT03459079
  3. https://clinicaltrials.gov/study/NCT03866369